



December 10, 2019

**Re: Inflammatory drug class changes effective January 1, 2020**

In October, we communicated our January 1, 2020, drug formulary changes, including those to the inflammatory drug class.<sup>1</sup> This letter is a reminder of the changes we will be making to the inflammatory drug class.

We will be adding quantity limits to all oral and self-injectable anti-inflammatory products; however, for certain conditions, we will allow higher dosing of the drugs listed below.<sup>2</sup>

Drug name	Condition(s)	Dosing
CIMZIA®	plaque psoriasis	4 vials or prefilled syringes per 28 days
HUMIRA®	Crohn's disease, hidradenitis suppurativa, rheumatoid arthritis	4 pens or prefilled syringes per 28 days
STELARA®	Crohn's disease, ulcerative colitis	1 prefilled syringe per 56 days

**What these changes mean to you and to your patients with Cigna-administered coverage**

We identified one or more of your patients with Cigna pharmacy benefits who received coverage for a drug affected by these changes, and we recently sent letters to them explaining the drug formulary changes. Therefore, **they may contact you directly to discuss these changes.**

**Additional information**

If you have questions about these changes, please call Cigna Customer Service at 800.88Cigna (882.4462).

Thank you for your shared commitment to help our customers better manage their medication therapies and improve their health outcomes.

Sincerely,

Jon Maesner, PharmD  
Chief Pharmacy Officer  
Cigna Pharmacy Management

<sup>1</sup>For Texas and Louisiana insured customers, the effective date may be deferred until the plan renewal date as required by state law.

<sup>2</sup>Depending on what the customer is taking this medication for, they may be able to receive coverage for amounts greater than what the quantity limits typically allow.

921410577201